Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com


Catalog No.: 52023
Cas No.: 1020172-07-9
Purity : 98%

Rebastinib(DCC-2036;DCC2036) is an inhibitor of tyrosine kinases TIE2 and ABL1.Rebastinib(DCC2036) can prevent primary tumor growth and lung metastasis in the PyMT breast cancer model.  Rebastinib is approximately 50 times more potent as an inhibitor of TIE2 than BCR-ABL. 

For research use only. We do not sell to patients.

Chemical Information

Iupac Chemical Name1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea 
SynonymsDCC-2036, Rebastinib, DCC2036, DCC 2036 
Molecular FormulaC30H28FN7O3 
Molecular Weight553.59 
CAS Number1020172-07-9
Related CAS

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
Request Bulk Quote Download MSDS Tel : +86-27-65522453   Email : sales@sun-shinechem.com
Formulationoff-white solid 
Storage3 years -20ºCpowder 6 months-80ºCin solvent 
Solubility5mg/ml in DMSO 
Shipping ConditionShipped under ambient temperature 
HS Code2933290090
TargetsRebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50 of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.
Cell study
Animal study
Clinical study

1. Anthony W. Tolcher, Pamela N. Munster, Lee S. Rosen, Curran Murphy, Christian Argueta, Keisuke Kuida, Rodrigo Ruiz-Soto, Filip Janku, An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors. DOI:10.1200/JCO.2019.37.15_suppl.TPS2666 Journal of Clinical Oncology 37, no. 15_suppl Published online May 26, 2019.

Chemical Structure

52023 - DCC-2036(Rebastinib) | CAS 1020172-07-9

Quick inquiry